Guideline Profile : Inflammatory bowel disease
You are here : Home > Formulary Search > Guideline Profile : Inflammatory bowel disease
Documentation
Guidelines (Local)
Guidelines (Local)
Guidelines (Local)
Guidelines (Local)
Drugs
Below are listed all drugs that are used to treat Inflammatory bowel disease.
Committee Recommendations (1)
The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed the SERMOG Inflammatory Bowel Disease high-cost drugs pathway.
Guideline Profile
Indication :
Inflammatory bowel disease
Keywords :
IBD, CD, Chronic Bowel Disorder, inflammatory bowel disease, corticosteroid, 5-ASA, aminosalicylate, UC, ulcerative Colitis, prednisolone, mesalazine, crohns, lower GI symptoms, Crohn's, Crohn's disease, biologic, NICE, biosimilar, Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, NICE, immunosuppressant, interleukin (IL)23 protein, DMARD, bDMARD, tsDMARD, Disease modulating, high cost immunomodulator, JAK inhibitor, Janus Kinase, Jakinib, Interleukin, IL 12/23, Immune checkpoint inhibitors, monoclonal antibodies, leukocyte integrin, sphingosine 1-phosphate (S1P) receptor modulator, anti-interleukin-23, anti-IL-23, SERMOG, SERMOG-06
Brand Names Include :
Humira, Hyrimoz, Amgevita, Hulio, Imraldi, Mylan, Yuflyma, Idacio, Jyseleca, Simponi, Remicade, Inflectra, Remsima, Flixabi, Zessly, Omvoh, Zeposia, Xeljanz, Rinvoq, Stelara, Entyvio, Entyvio SC, Skyriza,
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4